Shobha Shukla and Bobby Ramakant, CNS (Citizen News Service)
Dr Ekaphop Sirachainan who is the Vice President of Thai Society of Clinical Oncology (TSCO); faculty at Ramathibodi Hospital, Mahidol University; and a member of the Local Organising Committee of APLCC 2016 shared the highlights of some of the interesting oral and poster presentation abstracts. Asia Pacific Lung Cancer Conference (APLCC 2016) took place in Chiang Mai, Thailand (13-15 May 2016). It is organized by International Association for the Study of Lung Cancer (IASLC), Thai Society of Clinical Oncology (TSCO) Chiang Mai Lung Cancer Group, and other lead partners.
Few oral presentations highlighted by Dr Sirachainan:
• Award winning abstract of Dr. Takashi Seto, Department of Thoracic Onclogy, National Kyushu Cancer Centre, Japan, presents the results of ‘Prophylactic cranial irradiation (PCI) could not show the overall survival (OS) benefits of patients with extensive disease small cell lung cancer (ED-SCLC): A Japanese randomized phase III trial’. The study concluded that PCI after response to chemotherapy could not show the OS impact in patients with ED-SCLC.
• Award winning abstract of Dr. Keunchil Park, Samsung Medical Centre, Sungkyunkwan University School of Medicine, South Korea, on ‘Phase III trial of second-line Afatinib versus Erlotinib in patients with squamous cell carcinoma of the lung: tumour genetic analysis and survival outcomes’. The study found that OS (overall survival) and PFS (progression free survival) benefits with Afatinib over Erlotinib was consistent in all molecular subgroups analyzed.
• Award winning abstract of Dr. Ken O’Byrne, Princess Alexandra Hospital and Queensland University of Technology, Australia, presents results of a global Phase IIb trial on ‘First-line Afatinib versus Gefitinib in patients with EGFR mutation positive NSCLC: efficacy and safety in Asian patients’. The results showed that Afatinib significantly improved PFS, TTF (time to treatment failure) and ORR (overall response rate) versus Gefitinib in EGFRm+ patients.
• Abstract of Hao-ran Zhai, Pulmonary Division, Guangdong Lung Cancer Institute, China on ‘An alternative bronchial division procedure in right upper lobectomy (RUL) indicates better operative outcomes for lung cancer patients’. It compares an alternative surgical method of RUL with the conventional method with regard to safety and feasibility. The abstract concludes that conducting right upper lobectomy with the surgical procedure of aBVA via VATS (Video-assisted thoracic surgery) could result in better clinical benefits for primary lung cancer patients in terms of perioperative outcomes—less operative time and surgical costs— safety and technical feasibility.
• Abstract of Hong-Fei Gao, Guangdong Lung Cancer Institute, China, on ‘Study about Plasma dynamic monitoring of soluble c-Met level for EGFR-TKI treatment in advanced non-small cell lung cancer’. The study results showed that quantitative soluble c-Met in plasma by ELISA provided a non-invasive and sensitive assay to predict EGFR-TKI prognosis.
Few poster presentations especially mentioned by Dr Sirachainan:
• Award winning poster ‘Studying the cost-effectiveness analysis of second-line EGFR TKI in Thai patients with Advanced NSCLC’ by Ms.Tanavadee Siritanadeepun,, King Chulalongkorn Memorial Hospital, Thailand. The study concluded that in Thai patients with NSCLC, second-line EGFR TKI is cost-effective, as compared to second-line chemotherapy.
• ‘Mixed responses (MR) to systemic therapy in NSCLC patients evaluated by PET/CT indicate clinical significance for predicting survival and genetic intertumoral heterogeneity’ by Dr Zhong-Yi Dong, Guangdong Lung Cancer Institute, China. The results showed that MR was not a rare event in NSCLC patients and tended to occur in advanced lung adenocarcinoma treated with TKI. MR may result from inter-tumour heterogeneity and serve as an unfavourable prognostic factor for survival.
• ‘Impact of T790M genotype on post-progression survival of patients with exon 19 deletion versus those with L858R mutation’ by Dr Ee Ke, Guangdong Lung Cancer Institute, China. The study found that patients with L858R mutations in T790M-negative subgroup would probably survival longer than those with exon 19 deletions.
• Award winning poster ‘Salvage radiotherapy for locoregionally recurrent non-small cell lung cancer after resection’ by Dr. Jae-Sung Kim, Radiation Oncology, Seoul National University Bundang Hospital, South Korea. The review concluded that patients with locoregionally recurrent NSCLC showed favourable survival outcomes with salvage RT. Young age, single site recurrence, and the use of concurrent chemo radiotherapy were good prognostic factors of overall survival.
• Award winning poster on evaluating ‘Quantification of EGFR mutations in plasma circulating DNA by Droplet Digital PCR for patients with advanced NSCLC’ by Dr Qiu-Yi Zhang, Guangdong Lung Cancer Institute, China. The study concluded that plasma could be a novel surrogate in case of insufficient tissue specimens for EGFR gene detection. Droplet digital PCR could be a potential tool for quantification of EGFR mutations in plasma circulating DNA.
Shobha Shukla and Bobby Ramakant, CNS (Citizen News Service)
15 May 2016
 |
| Dr Ekaphop Sirachainan, Vice President Thai Society of Clinical Oncology |
Few oral presentations highlighted by Dr Sirachainan:
• Award winning abstract of Dr. Takashi Seto, Department of Thoracic Onclogy, National Kyushu Cancer Centre, Japan, presents the results of ‘Prophylactic cranial irradiation (PCI) could not show the overall survival (OS) benefits of patients with extensive disease small cell lung cancer (ED-SCLC): A Japanese randomized phase III trial’. The study concluded that PCI after response to chemotherapy could not show the OS impact in patients with ED-SCLC.
• Award winning abstract of Dr. Keunchil Park, Samsung Medical Centre, Sungkyunkwan University School of Medicine, South Korea, on ‘Phase III trial of second-line Afatinib versus Erlotinib in patients with squamous cell carcinoma of the lung: tumour genetic analysis and survival outcomes’. The study found that OS (overall survival) and PFS (progression free survival) benefits with Afatinib over Erlotinib was consistent in all molecular subgroups analyzed.
• Award winning abstract of Dr. Ken O’Byrne, Princess Alexandra Hospital and Queensland University of Technology, Australia, presents results of a global Phase IIb trial on ‘First-line Afatinib versus Gefitinib in patients with EGFR mutation positive NSCLC: efficacy and safety in Asian patients’. The results showed that Afatinib significantly improved PFS, TTF (time to treatment failure) and ORR (overall response rate) versus Gefitinib in EGFRm+ patients.
• Abstract of Hao-ran Zhai, Pulmonary Division, Guangdong Lung Cancer Institute, China on ‘An alternative bronchial division procedure in right upper lobectomy (RUL) indicates better operative outcomes for lung cancer patients’. It compares an alternative surgical method of RUL with the conventional method with regard to safety and feasibility. The abstract concludes that conducting right upper lobectomy with the surgical procedure of aBVA via VATS (Video-assisted thoracic surgery) could result in better clinical benefits for primary lung cancer patients in terms of perioperative outcomes—less operative time and surgical costs— safety and technical feasibility.
• Abstract of Hong-Fei Gao, Guangdong Lung Cancer Institute, China, on ‘Study about Plasma dynamic monitoring of soluble c-Met level for EGFR-TKI treatment in advanced non-small cell lung cancer’. The study results showed that quantitative soluble c-Met in plasma by ELISA provided a non-invasive and sensitive assay to predict EGFR-TKI prognosis.
Few poster presentations especially mentioned by Dr Sirachainan:
• Award winning poster ‘Studying the cost-effectiveness analysis of second-line EGFR TKI in Thai patients with Advanced NSCLC’ by Ms.Tanavadee Siritanadeepun,, King Chulalongkorn Memorial Hospital, Thailand. The study concluded that in Thai patients with NSCLC, second-line EGFR TKI is cost-effective, as compared to second-line chemotherapy.
• ‘Mixed responses (MR) to systemic therapy in NSCLC patients evaluated by PET/CT indicate clinical significance for predicting survival and genetic intertumoral heterogeneity’ by Dr Zhong-Yi Dong, Guangdong Lung Cancer Institute, China. The results showed that MR was not a rare event in NSCLC patients and tended to occur in advanced lung adenocarcinoma treated with TKI. MR may result from inter-tumour heterogeneity and serve as an unfavourable prognostic factor for survival.
• ‘Impact of T790M genotype on post-progression survival of patients with exon 19 deletion versus those with L858R mutation’ by Dr Ee Ke, Guangdong Lung Cancer Institute, China. The study found that patients with L858R mutations in T790M-negative subgroup would probably survival longer than those with exon 19 deletions.
• Award winning poster ‘Salvage radiotherapy for locoregionally recurrent non-small cell lung cancer after resection’ by Dr. Jae-Sung Kim, Radiation Oncology, Seoul National University Bundang Hospital, South Korea. The review concluded that patients with locoregionally recurrent NSCLC showed favourable survival outcomes with salvage RT. Young age, single site recurrence, and the use of concurrent chemo radiotherapy were good prognostic factors of overall survival.
• Award winning poster on evaluating ‘Quantification of EGFR mutations in plasma circulating DNA by Droplet Digital PCR for patients with advanced NSCLC’ by Dr Qiu-Yi Zhang, Guangdong Lung Cancer Institute, China. The study concluded that plasma could be a novel surrogate in case of insufficient tissue specimens for EGFR gene detection. Droplet digital PCR could be a potential tool for quantification of EGFR mutations in plasma circulating DNA.
Shobha Shukla and Bobby Ramakant, CNS (Citizen News Service)
15 May 2016
